
Micronoma, a pioneer in liquid biopsy technology, accurately detects and predicts early-stage cancer.
Micronoma, founded by leaders in microbiome research, is a pioneering company in liquid biopsy technology aimed at early cancer detection. The company's core mission is to improve lives by providing clinical-grade accuracy in detecting and predicting cancer through the interrogation of microbial signals. Micronoma focuses on utilizing microbiome markers in blood samples to identify early-stage cancer, offering a non-invasive and highly precise diagnostic tool.
Notable figures affiliated with Micronoma include its founders, who are recognized experts in microbiome research. The company has attracted significant attention from investors due to its innovative approach and potential impact on early cancer diagnosis. Key achievements include the development of a proprietary platform that leverages microbiome markers for cancer detection. Overall, Micronoma's work promises to revolutionize the field of oncology diagnostics, offering earlier and more accurate detection methods that could significantly improve patient outcomes.

Droplet Biosciences
dropletbiosci.com

Freenome
freenome.com

Epinoma
epinoma.com

Biomiic

Mercy BioAnalytics
mercybio.com

Oncodea
oncodea.com

Foresight Diagnostics
foresight-dx.com

Thrive Earlier Detection

Lucence
lucence.com

AOA Dx
aoadx.com

GRAIL
grail.com

Acuamark Diagnostics
acuamarkdx.com

Matrix-Bio

Naveris
naveris.com

MeCo Diagnostics
Companies similar to Micronoma include Droplet Biosciences, Freenome, Epinoma and Biomiic.
Micronoma was founded in 2019.
Micronoma's headquarters is located in San Diego, CA, US.
Micronoma's most recent funding round was for $11M (USD) in March 2022.
As of Mar 31, 2022, Micronoma has raised a total of $17.5M (USD).
Micronoma has 37 employees as of Feb 4, 2024.